

# Xbrane sends shareholder letter in connection with the proposed rights issue

**Xbrane Biopharma AB (publ) ("Xbrane" or the "Company"), (NASDAQ Stockholm: XBRANE) sends shareholder letter to answer common questions in connection to the proposed rights issue.**

Xbrane provides a shareholder letter to answer questions received from shareholders regarding the proposed rights issue. The shareholder letter is attached to this press release. Xbrane is available for questions during the extraordinary general meeting held on Thursday 22 February 2024 at 16:30 CET and at the presentation of Year-end report 2023 on Monday February 26, 2024 at 13:00 CET.

## Contacts

Martin Åmark, CEO  
M: +46 76 309 37 77  
E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR  
M: +46 76 325 60 90  
E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 27 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com)

## Attachments

[Xbrane sends shareholder letter in connection with the proposed rights issue](#)  
[Xbrane Letter To Shareholders](#)